COVID-19 Anti-Viral Medication
Harbison’s first shipment of COVID-19 anti-viral medication has arrived! It may be prescribed by a GP to treat infection, and consists of a course of four (4) tablets, twice-a-day, for five (5) days.
We believe the possibility of an effective treatment will permit a reassessment of the risks of COVID-19 in residential aged care.
What you need to know about Lagevrio
- Lagevrio (Molnupiravir) is an oral treatment for COVID-19, which means it is administered in the form of a tablet.
- Lagevrio was approved by the Therapeutic Goods Administration on 18 January 2022 and pending PBS approval is being preplaced by the Australian Government in residential Aged Care facilities.
- Lagevrio is an S4 medicine, which means it requires a prescription from a GP.
- Lagevrio can be effective in treating people with mild to moderate COVID-19 symptoms, who have no need for supplemental oxygen due to COVID-19, and who are at high risk of progression to hospitalisation or death.
- Lagevrio should be administered within five (5) days of symptom onset.
- A course of Lagevrio consists of four (4) tablets every 12-hours for five (5) days (40 tablets in total), swallowed with water with or without food.
- Consent is required for the administration of Lagevrio.
- Until Lagevrio is registered with the PBS, each prescription must be notified by the GP to the Commonwealth.
More information can be found via the link below.